Domov › Ploščatocelični karcinom glave in vratu › Kalifornija › Irvine
Klinične študije za Ploščatocelični karcinom glave in vratu v Irvine, CA
11 študij za Ploščatocelični karcinom glave in vratu išče udeležence na lokacijah v Irvine in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- City of Hope at Irvine Lennar, Irvine
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Vključevanje udeležencevFaza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Vključevanje udeležencevFaza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Vključevanje udeležencevFaza 1/2
- City of Hope, Irvine, Irvine
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vključevanje udeležencevFaza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 1
- City of Hope at Irvine Lennar, Irvine
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Vključevanje udeležencevFaza 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Vključevanje udeležencevFaza 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Vključevanje udeležencevFaza 1/2
- University of California, Irvine, Irvine
Študije za Ploščatocelični karcinom glave in vratu v drugih mestih
- Houston, TX47 študij
- Los Angeles, CA42 študij
- Boston, MA40 študij
- New York City, NY39 študij
- Nashville, TN39 študij
- St. Louis, MO28 študij
- Arlington, VA26 študij
- Philadelphia, PA26 študij
- Chicago, IL26 študij
- Atlanta, GA24 študij
- San Antonio, TX22 študij
- New Haven, CT22 študij
Druge študije v Irvine
- Nemalicelični pljučni rak25 študij
- Rak dojke23 študij
- Rak (vse vrste)17 študij
- Metastatski rak16 študij
- Rak pljuč15 študij
- Množni mielom14 študij
- Rak prostate14 študij
- Rak jajčnikov12 študij
- Rak mehurja11 študij
- Alzheimerjeva bolezen11 študij
- Kolorektalni rak10 študij
- Rak trebušne slinavke10 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.